Monoamine Oxidase Inhibitors
-
Subject Areas on Research
-
A history of the concept of atypical depression.
-
A history of the concept of atypical depression.
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
-
A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.
-
Acetylenics. 2. Synthesis and pharmacology of certain N,N-diakyl-3-phenylpropyn-2-amines. Some analogues with tryptamine-like behavioral effects in mice.
-
Adding a tricyclic antidepressant to a monoamine oxidase inhibitor.
-
Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.
-
Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial.
-
Atypical depression.
-
Biological therapies for posttraumatic stress disorder: an overview.
-
Catecholamine release and uptake in the mouse prefrontal cortex.
-
Cerebral amino acid, norepinephrine and nitric oxide metabolism in CNS oxygen toxicity.
-
Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions.
-
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.
-
Defining an appropriate management strategy for social anxiety disorder.
-
Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats.
-
Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
-
Efficacy of newer medications for treating depression in primary care patients.
-
Forms of atypical depression and their response to antidepressant drugs.
-
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
-
International advances in the treatment of social phobia.
-
MAO inhibition and control of anxiety following amitriptyline therapy. A pilot study.
-
Moclobemide in social phobia: a controlled dose-response trial.
-
Monoamine oxidase inhibitors in patients with chronic pain.
-
Neuroticism and personality disorder in depression.
-
Patient compliance with MAO inhibitor therapy.
-
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
-
Pharmacotherapy of social anxiety disorder.
-
Pharmacotherapy of social phobia.
-
Platelet MAO inhibition following tricyclic antidepressant therapy.
-
Practical aspects of MAO inhibitor therapy.
-
Predictors of response to monoamine oxidase inhibitors: do they exist?
-
Predictors of treatment response in patients with posttraumatic stress disorder.
-
Prevention of H2O2 generation by monoamine oxidase protects against CNS O2 toxicity.
-
Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.
-
Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela.
-
Relapse, side effects, and monoamine oxidase inhibition during long term use of isocarboxazid: a case report.
-
Revisiting monoamine oxidase inhibitors.
-
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
-
Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome.
-
Social phobia: biological aspects and pharmacotherapy.
-
Social phobia: issues in assessment and management.
-
The Newcastle Anxiety Depression Diagnostic Index in relationship to the effects of monoamine oxidase inhibitors and tricyclic antidepressants.
-
Tribulin in post-traumatic stress disorder.
-
Urinary metabolities of harmine in the rat and their inhibition of monoamine oxidase.
-
trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.